We profiled RBFOX2 mRNA expression levels in a large cohort of patients with AML (GSE13159, n = 500) and observed significantly higher RBFOX2 expression in multiple subtypes of AML compared with healthy bone marrow controls, which was validated by our western blot assay (Fig. 5a and Extended Data Fig. 7a). Here, RBFOX2 is linked to acute myeloid leukemia.